Know Cancer

forgot password

A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer

13 Months
Open (Enrolling)
Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors

Thank you

Trial Information

A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer

Inclusion Criteria:

- Subjects must have histologically proven neuroblastoma, brain tumor, or rare tumor
and confirmation of refractory or recurrent disease with histologic confirmation at
diagnosis or at the time of recurrence/progression

- Subjects must be age >12 months at enrollment.

- Subjects must be age ≤ 21 years at initial diagnosis.

- Subjects must have measurable disease as demonstrated by residual abnormal tissue at
a primary or metastatic site measuring more than 1 cm in any dimension by
standardized imaging (CT or MRI); tumor must be accessible for biopsy. Patients with
bone marrow only disease expected to be >75% tumor are eligible to enroll.

- Current disease state must be one for which there is currently no known curative

- Lansky or Karnofsky Score must be more than 50

- Subjects without bone marrow metastases must have an ANC > 750/μl

- Adequate liver function must be demonstrated, defined as:

1. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND

2. SGPT (ALT) < 10 x upper limit of normal (ULN) for age

- A negative serum pregnancy test is required for female participants of child bearing
potential (≥13 years of age or after onset of menses)

- Both male and female post-pubertal study subjects need to agree to use one of the
more effective birth control methods during treatment and for six months after
treatment is stopped. These methods include total abstinence (no sex), oral
contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants
(Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of
these cannot be used, contraceptive foam with a condom is recommended.

- Informed Consent: All subjects and/or legal guardians must sign informed written
consent. Assent, when appropriate, will be obtained according to institutional
guidelines. Voluntary consent for optional biology studies will be included.

Exclusion Criteria:

- Subjects who have received any cytotoxic chemotherapy within the last 7 days prior to
enrollment and 14 days prior to study treatment start date.

- Subjects who have received any radiotherapy to the primary sample site within the
last 14 days (radiation may be included in treatment decision after biopsy).

- Subjects receiving anti-tumor therapy for their disease or any investigational drug

- Subjects with serious infection or a life-threatening illness (unrelated to tumor)
that is > Grade 2 (NCI CTCAE V4.0), or active, serious infections requiring
parenteral antibiotic therapy.

- Subjects with any other medical condition, including malabsorption syndromes, mental
illness or substance abuse, deemed by the Investigator to be likely to interfere with
the interpretation of the results or which would interfere with a subject's ability
to sign or the legal guardian's ability to sign the informed consent, and subject's
ability to cooperate and participate in the study

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic mRNA expression arrays and DNA Mutation Panels using predictive modeling

Outcome Description:

The definition of feasibility for this study will include: "Enrollment onto study, RNA expression profile completed, DNA Mutation Panel completed, genomic analysis and report generation, tumor board held with treatment decision, treatment review completed and start of treatment by 21 days post biopsy/surgical resection date, and then completion of 1 cycle of therapy."

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Giselle Sholler, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Van Andel Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

February 2013

Completion Date:

February 2016

Related Keywords:

  • Neuroblastoma
  • Medulloblastoma
  • Brain Tumors
  • Rare Tumors
  • Brain Neoplasms
  • Medulloblastoma
  • Neuroblastoma



Medical University of South Carolina Charleston, South Carolina  29425-0721
Vanderbilt-Ingram Cancer Center Nashville, Tennessee  37232-6838
Phoenix Children's Hospital Phoenix, Arizona  85016-7710
Kapiolani Medical Center for Women and Children Honolulu, Hawaii  96826
Children's Mercy Hospitals and Clinics Kansas City, Missouri  64108
Rady Children's Hospital San Diego, California  92123
National Cancer Institute Bethesda, Maryland  20892-1922
Connecticut Children's Hospital Hartford, Connecticut  06106
Arnold Palmer Hospital for Children- MD Anderson Orlando, Florida  32806
Helen DeVos Children's Hospital Grand Rapids, Michigan  49503
Cardinal Glennon Children's Medical Center St. Louis, Missouri  63104
Levine Children's Hospital Charlotte, North Carolina  28204
Dell Children's Blood and Cancer Center Austin, Texas  78723
Primary Children's Hospital Salt Lake City, Utah  84113